After failing to enhance total survival in unresectable metastatic bladder most cancers in a section 3 trial, this indication will probably be withdrawn in america for the immunotherapy durvalumab (Imfinzi), AstraZeneca introduced.
The withdrawal doesn’t have an effect on this indication outdoors america, nor does it have an effect on different accredited durvalumab indications inside america.
For instance, durvalumab stays accredited by the US Meals and Drug Administration (FDA) within the curative-intent setting of unresectable, stage III non–small cell lung most cancers after chemoradiotherapy and for the remedy of extensive-stage small cell lung most cancers.
The corporate is continuous with medical trials of durvalumab in varied mixtures for the remedy of bladder most cancers.
Granted Accelerated Approval
Durvalumab was granted accelerated approval in Could 2017 by the FDA particularly for the remedy of sufferers with regionally superior or metastatic urothelial carcinoma who expertise illness development throughout or following platinum-containing chemotherapy or who expertise illness development inside 12 months of neoadjuvant or adjuvant remedy with that chemotherapy.
That accelerated approval was primarily based on the surrogate markers of tumor response price and length of response from Research 1108, a section 1/2 trial. On this trial, the general response price was 17.8% in a cohort of 191 sufferers with regionally superior or metastatic urothelial most cancers that had progressed throughout or after a platinum-based routine.
Nevertheless, within the confirmatory section 3 DANUBE trial in sufferers with unresectable metastatic bladder most cancers, neither durvalumab nor durvalumab plus tremelimumab met the first endpoint of enhancing total survival as compared with standard-of-care chemotherapy.
“Whereas the withdrawal in beforehand handled metastatic bladder most cancers is disappointing, we respect the ideas FDA set out when the accelerated approval pathway was based,” stated Dave Fredrickson, government vp, Oncology Enterprise Unit, AstraZeneca, in an organization press assertion.
Nick Mulcahy is an award-winning senior journalist for Medscape. He beforehand freelanced for HealthDay and MedPageToday and had bylines in WashingtonPost.com, MSNBC, and Yahoo. Electronic mail: firstname.lastname@example.org and on Twitter: @MulcahyNick.
For extra from Medscape Oncology, be part of us on Twitter and Fb.